Abstract Search

ea0081p532 | Adrenal and Cardiovascular Endocrinology | ECE2022

Covid-19 in patients with hypocortisolism: clinical syndrome, disease duration and glucocorticoid replacement therapy

Simeoli Chiara , Schettino Serafina , La Rocca Angelica , Di Paola Nicola , Massimo Crescenzo Erminio , Ciardella Francesco , Mazzarella Alessandro , Pivonello Claudia , Colao Annamaria , Pivonello Rosario

Coronavirus disease caused by SARS-CoV-2 virus (Covid-19) is associated with a variable clinical syndrome, ranging from a mild-moderate to a severe disease, progressing towards acute respiratory distress syndrome. Hypocortisolism is associated with a depletion of innate immunity and disruption of immune response, which could contribute to an increased risk of infection and development of a severe disease. Glucocorticoid (GC) replacement therapy(GCRT), especially if administere...

0 shares

ea0090p811 | Late-Breaking | ECE2023

Comparison of Metyrapone, OSilodrostat and KEToconazolE in the short-term thERapy of endogenous Cushing’s syndrome: preliminary results of the MOSKETEER study

Detomas Mario , Simeoli Chiara , Ceccato Filippo , Aulinas Maso Ana , Dolce Pasquale , Rubinstein German , Antonini Simone , Stelmachowska-Banaś Maria , Minnetti Marianna , Corsello Andrea , Dischinger Ulrich , Di Paola Nicola , Voltan Giacomo , Santos Vives Alicia , Braun Leah , Mazzarella Alessandro , DEUTSCHBEIN Timo , Lania Andrea , Isidori Andrea , Reincke Martin , Carla Scaroni , M Webb Susan , Pivonello Rosario , Fassnacht Martin , Altieri Barbara

Background: Steroid synthesis inhibitors, like metyrapone, osilodrostat, and ketoconazole are used as second-line treatment in all types of endogenous Cushings syndrome (CS). However, a direct comparison of these three drugs is missing. This study aimed to compare these drugs in the short-term therapy of CS.Design: Retrospective multicenter study involving 15 European centers.Methods: Patients with CS treated with metyrapone,...

5 shares

ea0093oc14 | Oral communication 2: Neuroendocrinology | EYES2023

Comparison of metyrapone, osilodrostat and ketoconazole in the short-term therapy of endogenous Cushing’s syndrome: Preliminary results of the Mosketeer study

Detomas Mario , Simeoli Chiara , Di Paola Nicola , Mazzarella Alessandro , Pivonello Rosario , Ceccato Filippo , Voltan Giacomo , Scaroni Carla , Aulinas Anna , Santos Alicia , Webb Susan , Rubinstein German , Braun Leah , Reincke Martin , Dolce Pasquale , Antonini Simone , Lania Andrea , Stelmachowska-Banaś Maria , Cylke-Falkowska Karolina , Minnetti Marianna , Isidori Andrea M. , Corsello Andrea , Gilis-Januszewska Aleksandra , Minasyjan Mari , Sambula Lana , Kastelan Darko , Deutschbein Timo , Haberbosch Linus , Dischinger Ulrich , Fassnacht Martin , Altieri Barbara

Background: Steroid synthesis inhibitors, like metyrapone, osilodrostat, and ketoconazole are used as second-line treatment in all types of endogenous Cushings syndrome (CS). However, a direct comparison of these three drugs is missing. This study aimed to compare these drugs in the short-term therapy of CS.Design: Retrospective multicenter study involving 16 centers worldwide.Methods: Patients with CS treated with metyrapone...

2 shares

Endocrine Abstracts

Covid-19 in patients with hypocortisolism: clinical syndrome, disease duration and glucocorticoid replacement therapy

Comparison of Metyrapone, OSilodrostat and KEToconazolE in the short-term thERapy of endogenous Cushing’s syndrome: preliminary results of the MOSKETEER study

Comparison of metyrapone, osilodrostat and ketoconazole in the short-term therapy of endogenous Cushing’s syndrome: Preliminary results of the Mosketeer study

BiosciAbstracts